22 August 2019

Interim Report 1 January – 30 June 2019

Attachments Download report
Scandion Oncology A/S (”Scandion Oncology” or the “Company”) hereby publishes the Half-Year Report for the period 1 January – 30 June 2019. The Half-Year Report is available on the Company’s website ( Below is a summary of the report.

Reporting period April 2019 – June 2019

  • Net sales amounted to DKK 0 (0).
  • Operating profit was -4.851m DKK (-2.366).
  • Cash and bank assets amounted to 3.160 m DKK (327).
  • Result per share was DKK -0.33 (-0.23).

Reporting period January 2019 – June 2019

  • Net sales amounted to DKK 0 (0).
  • Operating profit was -7.196 m DKK (-3.061).
  • Cash and bank assets amounted to 3.160 m DKK (327).
  • Result per share was DKK -0.49 (-0.32).
  • Solidity was 86% (37).

Highlights during the period

  • Scandion Oncology announced that SCO-101 tablets have been successfully produced as a pilot production on June 26th. The Company expects to initiate its first clinical Phase II study with drug resistant cancer in late 2019.
  • Scandion Oncology announced on June 27th that the Company has identified the four clinical sites where the lead candidate drug SCO-101 will be tested in combination with chemotherapy in patients with metastatic and drug resistant colorectal cancer.
  • Scandion Oncology announced on June 6th that the Company appointed Chairman and Vice-Chairman of its Board of Directors. Jørgen Bardenfleth continues as Chairman of the Board and Peter Høngaard Andersen will take the position as Vice-Chairman of the Board.
  • In early April Scandion Oncology obtained EU Funding (SME Instruments Phase 1) for SCO-101 in drug resistant breast cancer patients.
  • Scandion Oncology signed collaboration agreement with University of Copenhagen regarding co-development of a class of drug candidates that reverts anti-cancer drug resistance.
  • Scandion Oncology received an “Intention to Grant” notice from the European Patent Office regarding its patent application covering SCO-101 in combination with specific topoisomerase I inhibitors to treat various cancers.

Highlights after the period

  • Scandion Oncology announces that the rights issue in the Company was oversubscribed by 200%. Scandion Oncology will be provided approx. 29.3 million SEK before issue costs. In addition, if all warrants are fully exercised, Scandion Oncology will in Q3, 2020, obtain additional 12.4 million SEK before issue costs.
  • Scandion Oncology releases first status on Dutch collaboration on SCO-101 (EU grant) regarding endocrine treatment of breast cancer cell lines.

For further information regarding Scandion Oncology, please contact:

Nils Brünner, CEO

Phone: +45 26 14 47 08


Scandion Oncology A/S is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro-studies SCO-101 restores chemotherapy sensitivity in resistant patient-derived cancer cells. Moreover, in animal studies, the company’s leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now ready to initiate clinical phase II trials with its lead compound, SCO-101 in patients with drug resistant cancer. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018.

Attachments Download report